Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Abbott Laboratories (ABT)

NYSE: ABT · Medical Devices · Abbott Park, IL

Our rating: Neutral

Neutral reaffirmed at $113.60, moderate conviction, November 5, 2026.

Breaks if: The Neutral call turns Positive if Abbott reports two consecutive quarters of organic revenue growth above 8% year on year, suggesting an acceleration the current multiple does not fully price in. It turns Cautious if free cash flow margin slips below 14% for two straight quarters — down from the current roughly 16.7% implied by reported figures — signaling that the cash-conversion quality underpinning the thesis is eroding rather than holding.

Key figures

Market value$178.4B
Revenue, last 12 months$48.2B
Net income, last 12 months$4.7B
Free cash flow, last 12 months$6.8B
Price to earnings37.9×
Free cash flow yield3.8%
Dividend yield2.4%
Operating margin13.8%
Return on equity9.2%
Beta to the S&P 5000.17
Volatility, annualized24.2%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$13.0B14.5%$0.53$1.2B
June 30, 2026$12.6B13.0%$0.53$2.0B
March 31, 2026$11.2B7.8%$0.61$916M
December 31, 2025$11.5B4.4%$1.02$2.6B
September 30, 2025$11.4B6.9%$0.94$2.3B
June 30, 2025$11.1B7.4%$1.01$1.5B
March 31, 2025$10.4B4.0%$0.76$933M
December 31, 2024$11.0B7.2%$5.26$2.1B

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

18 ledger entries and 38 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.